Our mission is to develop novel Id-protein targeted small molecule therapeutics               in oncology and vascular diseases of the eye the eye.

Background and History of the Company


We are a public bio-pharmaceutical company dedicated to the development and commercialization of a novel, inexpensive treatment for vascular diseases including many forms of cancer and macular degeneration.

Business Strategy


AngioGenex was created to capture the full potential of the Id platform. It currently owns unencumbered exclusive world-wide rights under issued and pending patents to a novel class of drugs that target the ID proteins. Central to this strategy is the company’s symbiotic relationship with MSKCC, which includes a coordinated R&D program and clinical trial plan. MSKCC holds common stock in the Company that was granted in return for the efforts it contributed to Dr. Benezra’s early efforts in discovering the role of the ID proteins and their potential as targets for disease intervention.

SEC Filings

AngioGenex is a publicly traded company, trading on the OTC exchange with the ticker symbol AGGX. Our filings with the Securities and Exchange Commission(SEC) can be found here.

Contact Us

Our office is located at:

425 Madison Avenue, Suite 902

New York, NY, 10017

Phone: 212-874-6608

Fax: 212-874-5027

Email:  Info@angiogenex.com

For immediate questions regarding our technology, reach Dr. Robert Benezra at benezrar@angiogenex.com or 646-888-2112

For immediate administrative and financial questions, reach Mr. Michael Strage at stragem@angiogenex.com or 347-468-6799

For all other queries, reach us at 212-874-6608 or via email at info@angiogenex.com

Patent Counsel 

Jeffrey J. King, Esq.
5000 Carillon Point - Suite 400
Kirkland, WA 98033
Telephone: (425) 576-4235
Facsimile: (425) 576-4236
Direct Dial: (425) 281-6574
Email: jking@patentnetworks.com


Corporate Counsel

Sophia Hudson

Davis Polk & Wardwell LLP

450 Lexington Avenue  |  New York, NY 10017

+1 212 450 4762 tel  |  +1 212 701 5762 fax


Transfer Agent

Nevada Agency and Transfer Company 
50 West Liberty Street, Suite 880 
Reno, Nevada 89501 
Tel: 775-322-0626
Fax: 775-322-5623 
Email: corpserve@natco.org 
Website: www.natco.org 

© 2017 Angiogenex. All rights reserved.